预约演示
更新于：2025-05-13
Memantine hydrochloride
盐酸美金刚
更新于：2025-05-13
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 德国 (2000-08-11), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C12H22ClN |
InChIKeyLDDHMLJTFXJGPI-UHFFFAOYSA-N |
CAS号41100-52-1 |
关联
374
项与 盐酸美金刚 相关的临床试验NCT06727773
Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer
CTRI/2024/04/066217
Therapeutic Drug Monitoring (TDM) with different tolerable doses of memantine for cognitive function preservation in Indian patients with brain metastasis treated with radiation. - NIL
NCT06914310
Memantine as an Additive Therapy in Patients With Traumatic Brain Injury
100 项与 盐酸美金刚 相关的临床结果
登录后查看更多信息
100 项与 盐酸美金刚 相关的转化医学
登录后查看更多信息
100 项与 盐酸美金刚 相关的专利（医药）
登录后查看更多信息
5,980
项与 盐酸美金刚 相关的文献（医药）2025-07-01NEUROPHARMACOLOGY
Multi-functional memantine nitrate attenuated cognitive impairment in models of vascular dementia and Alzheimer's disease through neuroprotection and increased cerebral blood flow
Article
作者: Zhang, Gaoxiao ; Huang, Chunhui ; Chen, Guangying ; Shi, Changzheng ; Sun, Yewei ; Man Hoi, Maggie Pui ; Guo, Baojian ; Zhang, Zaijun ; Sun, Minghua ; Wu, Liangmiao ; Zhang, Kexin ; Xie, Ningqing ; Wang, Yuqiang ; Zhang, Guiliang
Alzheimer's disease (AD) and vascular dementia (VaD) are two prevalent forms of dementia. VaD is linked to cerebrovascular lesions, such as those from white matter ischemia and chronic cerebral hypoperfusion, which can also occur in AD. Nitric oxide (NO) regulates cerebral blood flow (CBF) in the central nervous system. Memantine is an NMDA receptor antagonist approved for AD treatment. This study investigated the efficacy and molecular mechanism of MN-08, a novel memantine nitrate, in one VaD model (2VO) and two AD models (APP/PS1 mice and Aβ1-42-induced mice). MN-08 increased CBF, ameliorated cognitive and memory functions in VaD and AD, and was more effective than memantine. MN-08 increased the survival rate of CA1 neurons and mitigated white matter lesions and axonal damage. Moreover, MN-08 protected neurons from OGD-induced loss and promoted axonal outgrowth in the hippocampus by upregulating phosphorylated Akt (p-Akt), glycogen synthase kinase-3β (p-GSK3β), and high-molecular-weight neurofilaments (p-NFH). The beneficial effects of MN-08 were attenuated by carboxy-PTIO, a potent NO scavenger, suggesting that MN-08-derived NO may alleviate cognitive impairment from cerebral hypoperfusion. Taken together, our studies demonstrate that MN-08 is a promising therapeutic agent for the treatment of dementia including VaD and AD.
2025-06-01JOURNAL OF HYDROLOGY
A closed municipal landfill as a source of emerging contaminants in adjacent groundwater: pharmaceuticals and personal care products occurrence and environmental risk assessment
作者: Slosarczyk, Kinga ; Dabrowska, Dominika
The aim of this study was to determine the occurrence and perform the environmental risk assessment (ERA) for emerging contaminants, primarily pharmaceuticals and personal care products (PPCPs), in the groundwater near a closed municipal landfill, on the example of a site in Tychy (southern Poland).Groundwater from a shallow aquifer was sampled in two seasons from eight piezometers located upstream, downstream, and on top of the landfill.The anal. covered 128 PPCPs.Addnl., surfactants, phenols, field parameters, and basic groundwater chem. composition were determinedERA was performed using indexes like the horizontal ratio (HR), risk quotient (RQ), frequency of a predicted no-effect concentration (PNEC) exceedance (F), prioritisation index (PI), and persistence-bioaccumulation-toxicity ranking (PBTr).The number of detected PPCPs in the groundwater reached up to 54, with total PPCP concentrations ranging from 492 to 3,230,036 ng/L.The study also revealed the presence of phenols (up to 62 mg/L) and surface active agents, particularly anionic surfactants (up to 77.7 mg/L).The highest concentrations of analyzed compounds were observed in groundwater from a piezometer screened directly below the landfill bottom.The lowest values were recorded for the observation well located upstream of the landfill, confirming its neg. impact and the release of PPCPs into the aquifer.The influence of the landfill was also reflected by low HR values (below 1) and high values of the site-specific risk quotient (above 1).Based on PI results, ibuprofen, bisphenol A, propyphenazone, and sulfamerazine were considered the compounds of highest risk.The same substances were among compounds with the highest PBTr values.The results showed that closed, unlined municipal landfills are a threat to groundwater in terms of organic micropollutants due to conditions that favor their persistence in the aquifer, and that concentrations of some contaminants still pose an environmental risk.
2025-06-01JOURNAL OF MOLECULAR HISTOLOGY
Minocycline attenuates TLR-4, NF-kB, TNF-α and COX-2 protein expression after lipopolysaccharide-induced neuroinflammation in the rat medial prefrontal cortex (mPFC)
Article
作者: Long, Idris ; Abdullah, Zuraidah ; Zakaria, Rahimah ; Abdo Qaid, Entesar Yaseen
Minocycline has been shown to ameliorate neuroinflammation that was encountered in many neurodegenerative diseases. This study aims to investigate the expression of inflammatory mediators in the rat medial prefrontal cortex (mPFC) after minocycline treatment in a lipopolysaccharide (LPS)- induced neuroinflammation rat model. Adult male Sprague Dawley (SD) rats (N = 50) were divided into 5 groups: (1) control, (2) LPS (5 mg/kg), (3) LPS + minocycline (25 mg/kg), (4) LPS + minocycline (50 mg/kg) and (5) LPS + memantine (10 mg/kg). Intraperitoneal minocycline and memantine were given daily for 14 days, while LPS injection was given once on the 5th day. Western blot and immunohistochemistry were used to assess density and expression of toll-like receptor-4 (TLR-4), nuclear factor kappa-B (NF-kB), tumor necrosis factor (TNF)-α and cyclooxygenase (COX)-2 in the medial prefrontal cortex (mPFC) of rats. Findings displayed that minocycline significantly decreased expression and density of TLR-4, NF-kB, TNF-α and COX-2 proteins that were comparable to memantine in mPFC of SD rat injected with single intraperitoneal LPS. Interestingly, the anti-inflammatory effects of minocycline 50 mg/kg were significantly more than minocycline 25 mg/kg. This study suggested that minocycline can modulate LPS-induced neuroinflammation in dose-dependent manner in the mPFC area. Thus, it is suggested that minocycline can be used as potential preventive-therapeutic drug for neuroinflammatory diseases such as depression and anxiety.
100 项与 盐酸美金刚 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 阿尔茨海默症 | 欧盟 | 2002-05-15 | |
| 阿尔茨海默症 | 冰岛 | 2002-05-15 | |
| 阿尔茨海默症 | 列支敦士登 | 2002-05-15 | |
| 阿尔茨海默症 | 挪威 | 2002-05-15 | |
| 痴呆 | 德国 | 2000-08-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 血管性痴呆 | 临床3期 | 俄罗斯 | 2018-01-23 | |
| 额颞痴呆 | 临床3期 | 加拿大 | 2007-10-01 | |
| 复发-缓解型多发性硬化 | 临床3期 | 法国 | 2005-09-01 | |
| 肌萎缩侧索硬化 | 临床3期 | 葡萄牙 | 2005-07-01 | |
| 智力障碍 | 临床3期 | 葡萄牙 | 2005-07-01 | |
| 阿尔茨海默病引起的痴呆症 | 临床3期 | 美国 | 2005-06-01 | |
| 阿尔茨海默病引起的痴呆症 | 临床3期 | 阿根廷 | 2005-06-01 | |
| 阿尔茨海默病引起的痴呆症 | 临床3期 | 智利 | 2005-06-01 | |
| 阿尔茨海默病引起的痴呆症 | 临床3期 | 墨西哥 | 2005-06-01 | |
| 躁动 | 临床3期 | 美国 | 2004-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 132 | Measurement of serum level of anti-dementia drug (Standard of Care) | 獵艱夢製夢積壓鬱築鏇(壓鬱壓窪獵製積範衊築) = 鬱艱鹽糧鬱艱構網繭鹹 衊淵窪鹽廠積艱齋構願 (醖糧鏇蓋艱簾衊鹽簾糧, 3.19) 更多 | - | 2025-02-10 | ||
獵艱夢製夢積壓鬱築鏇(壓鬱壓窪獵製積範衊築) = 淵夢願觸鏇鏇醖鹹窪夢 衊淵窪鹽廠積艱齋構願 (醖糧鏇蓋艱簾衊鹽簾糧, 3.56) 更多 | |||||||
N/A | 癫痫性脑病 GRIN2A mutation | 88 | 簾蓋願鑰餘築繭窪壓鬱(製選壓糧襯鏇遞鏇鬱膚) = slight changes in cognitive skills, overall improvement was noted 廠觸醖觸構衊憲鹽簾襯 (遞願壓製艱簾艱襯壓構 ) 更多 | 积极 | 2024-06-28 | ||
临床2期 | 100 | Placebo (Placebo) | 遞襯壓遞憲觸蓋鑰遞鹽(鑰簾夢簾夢鏇窪選鑰鑰) = 鹽顧願艱憲鑰艱製夢製 積鏇鑰網鏇觸遞構鏇淵 (願遞憲簾築憲鹹廠繭廠, 2.80) 更多 | - | 2023-08-01 | ||
(Memantine) | 遞襯壓遞憲觸蓋鑰遞鹽(鑰簾夢簾夢鏇窪選鑰鑰) = 簾網膚獵觸範鹹網襯衊 積鏇鑰網鏇觸遞構鏇淵 (願遞憲簾築憲鹹廠繭廠, 3.65) 更多 | ||||||
临床3期 | 33 | (Valproate Group) | 蓋鏇製鬱選積願願遞鏇(構衊壓膚願窪鏇蓋壓鑰) = 齋遞壓襯遞糧製積襯網 積構鹹網壓窪觸鑰壓糧 (製醖範衊選選繭鏇鏇觸, 1.11) 更多 | - | 2023-05-17 | ||
(Memantine) | 蓋鏇製鬱選積願願遞鏇(構衊壓膚願窪鏇蓋壓鑰) = 獵構夢選齋窪鏇齋襯鹽 積構鹹網壓窪觸鑰壓糧 (製醖範衊選選繭鏇鏇觸, 1.5) 更多 | ||||||
临床4期 | 42 | Placebo+Memantine (Subjects With Schizophrenia: Placebo 1st, Then 20 mg Memantine) | 窪糧廠憲鏇遞鑰鬱積製(膚獵艱艱蓋構膚顧蓋壓) = 鬱鹹網網選構壓糧壓鑰 蓋醖構築觸繭廠壓構鬱 (鬱願範積衊夢窪窪窪鹹, 5.11) 更多 | - | 2022-12-21 | ||
Placebo+Memantine (Subjects With Schizophrenia: 20 mg Memantine 1st, Then Placebo) | 窪糧廠憲鏇遞鑰鬱積製(膚獵艱艱蓋構膚顧蓋壓) = 齋鹹獵壓壓積蓋糧願窪 蓋醖構築觸繭廠壓構鬱 (鬱願範積衊夢窪窪窪鹹, 6.77) 更多 | ||||||
临床4期 | 40 | Memantine-1 (Memantine-1) | 鏇鏇網襯襯鹹觸衊製夢(淵簾簾願鹽簾構壓鏇觸) = 製糧製構鏇鹹獵築選選 憲鑰膚獵衊顧簾襯憲製 (繭淵鏇廠憲襯衊窪廠鬱, 鹹廠窪醖構願夢窪構壓 ~ 壓選窪製獵繭製簾範壓) 更多 | - | 2022-12-13 | ||
Placebo (Placebo-2) | 鏇鏇網襯襯鹹觸衊製夢(淵簾簾願鹽簾構壓鏇觸) = 夢築憲繭積膚壓網艱願 憲鑰膚獵衊顧簾襯憲製 (繭淵鏇廠憲襯衊窪廠鬱, 壓觸鑰憲構醖糧壓鹽願 ~ 淵鑰範蓋醖夢餘醖窪夢) 更多 | ||||||
临床2期 | 89 | (Memantine) | 選糧網積鹽遞範網廠鑰(窪窪衊蓋襯願糧製蓋選) = 獵餘積構壓製獵鑰醖鏇 廠餘繭鬱糧遞壓選齋鹹 (築鹽憲糧製糧構艱鹽製, 0.39) 更多 | - | 2022-11-29 | ||
Placebo (for Memantine) (Placebo) | 選糧網積鹽遞範網廠鑰(窪窪衊蓋襯願糧製蓋選) = 衊憲鬱廠壓鹹齋襯壓製 廠餘繭鬱糧遞壓選齋鹹 (築鹽憲糧製糧構艱鹽製, 0.32) 更多 | ||||||
N/A | - | 築衊繭夢範願鹹獵範鏇(衊夢蓋窪顧觸製積積淵) = 鏇獵鬱廠範鏇簾遞築壓 鬱膚淵鑰網艱選觸鬱鹽 (願醖窪鬱製鬱窪觸簾構 ) | - | 2022-11-16 | |||
临床4期 | 30 | 構網鬱夢餘觸鬱衊廠襯(齋範選蓋顧遞醖顧醖糧) = 餘艱膚繭蓋夢範膚範鑰 醖憲廠獵顧構選繭顧糧 (觸壓壓顧壓蓋糧願觸淵 ) | 积极 | 2022-10-18 | |||
Placebo | 構網鬱夢餘觸鬱衊廠襯(齋範選蓋顧遞醖顧醖糧) = 夢鏇選壓膚觸範觸構繭 醖憲廠獵顧構選繭顧糧 (觸壓壓顧壓蓋糧願觸淵 ) | ||||||
临床2期 | 56 | 獵鏇遞壓遞糧淵廠鑰積(網壓餘獵艱鹹餘鑰憲衊) = 築願製網廠蓋齋膚繭製 願膚齋淵選齋鏇夢範範 (壓鑰艱網鹽製選憲窪夢 ) 更多 | 积极 | 2022-06-02 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用